Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02706639 · ClinicalTrials.gov registry record

Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank

A clinical trial of Cardiovascular Disease and Williams Syndrome, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Recruiting
Registry status
1,099
Enrollment target
3
Study locations

NCT02706639: Recruiting study of Cardiovascular Disease and Williams Syndrome, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT02706639 is a study of Cardiovascular Disease and Williams Syndrome that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,099 participants, below the 2,689-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02706639, a study of Cardiovascular Disease and Williams Syndrome, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

RECRUITING
Registry status
1,099 participants
Enrollment target
3
Study locations

Study Summary

Williams syndrome is a rare genetic disorder occurring in 1:8000-12,000 individuals. It is caused by the deletion of 25-27 coding genes, including elastin (ELN) on the 7th human chromosome. Haploinsufficiency for these genes leads to the features of the condition, including: * Distinctive facial features; * Characteristic vascular problems including hypertension, focal vascular stenosis, (when present in the aorta this is referred to as SVAS), vascular stiffness and differences in heart rate variability; * Endocrine abnormalities including hypercalcemia, hypothyroidism, and early puberty; * Metabolic concerns with colic and failure to gain weight in infancy and obesity and early glucose intolerance in adulthood; * Characteristic neurocognitive profile comprised of cognitive impairment, high sociality with concurrent social awkwardness, difficulty with visual-spatial tasks, relative strengths in speech, and lack of social fear; * Anxiety and chronic pain in adulthood Most individuals with WS carry the same basic deletion on Chromosome 7q11.23. However, each feature may present as mild or more severe in any given individual. Variation in the presence and severity of these vascular phenotypes remains unexplained. The supravalvar aortic stenosis (SVAS) phenotype is caused by haploinsufficiency for elastin. This can come about due to the WS deletion (as above) or due to heterozygous variation in elastin (ELN) gene itself in this region. When this protein is reduced, connective tissues lose its strength, flexibility, and overall support. When this happens in the aorta, it may cause vascular narrowing that presents as shortness of breath, chest pain, and even heart failure if left untreated. Narrowing also occurs in other vessels especially the pulmonary and renal arteries. Changes in non-vascular elastic tissues such as the skin and lungs also occur. As in WBS, phenotypic variation also occurs in people with ELN gene changes--This variability remains unexplained despit

Primary Outcome

The overall objective of this study is to collect historical information and to bank DNA, cells and tissue from individuals with WS and SVAS to facilitate future research into the many phenotypes seen in these individuals.

Study Locations (3)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Missouri

  • Washington University School of Medicine - St Louis

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 1,099 participants
Start Date 2016-05-11
Est. Completion 2040-09-25

What NCT02706639 shows while recruiting

NCT02706639 is an observational study that tracks outcomes without assigning an intervention. Its 1,099 participants enrollment target places it among the larger protocols in the corpus, below the 2,689-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (59% lower).

The record links to 3 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 0 interventions.

NCT02706639 reports a single indexed study location in Maryland, Missouri, Ohio.

Frequently Asked Questions

What is clinical trial NCT02706639 about?

NCT02706639 is a clinical study titled "Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank". Williams syndrome is a rare genetic disorder occurring in 1:8000-12,000 individuals. It is caused by the deletion of 25-27 coding genes, including elastin (ELN) on the 7th human chromosome. Haploinsufficiency for these genes leads to the features of the condition, including: * Distinctive facial fe...

What is the current status of trial NCT02706639?

This trial is currently recruiting. The enrollment target is 1,099 participants. The study started on 2016-05-11. Estimated completion is 2040-09-25.

What conditions does trial NCT02706639 study?

This clinical trial studies the following conditions: Cardiovascular Disease, Williams Syndrome, Supravalvular Aortic Stenosis.

Who is sponsoring clinical trial NCT02706639?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02706639 being conducted?

This trial has 3 study locations across Maryland, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02706639's enrollment target sits among peer trials

1,099 27th of 137 higher than 111 of 137 other Cardiovascular Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00710112 · 1,100 participants

    Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants

  • NCT02688517 · 1,100 participants

    Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

  • NCT04743765 · 1,100 participants · NA

    HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

  • NCT05638581 · 1,100 participants · Phase 3

    Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02706639, the US trial registry maintained by the National Library of Medicine. NCT02706639 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.